Royal Bank of Canada’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-5
Closed 7809
2022
Q4
$0 Sell
5
-35
-88% -$14 ﹤0.01% 8065
2022
Q3
$0 Hold
40
﹤0.01% 8152
2022
Q2
$0 Hold
40
﹤0.01% 8047
2022
Q1
$0 Hold
40
﹤0.01% 8204
2021
Q4
$0 Sell
40
-2,806
-99% -$5K ﹤0.01% 8095
2021
Q3
$10K Sell
2,846
-1,530
-35% -$4.77K ﹤0.01% 6982
2021
Q2
$17K Sell
4,376
-43,681
-91% -$181K ﹤0.01% 6662
2021
Q1
$298K Buy
48,057
+47,710
+13,749% +$423K ﹤0.01% 4625
2020
Q4
$3K Buy
+347
New +$3.18K ﹤0.01% 6829

Other funds holding MTCR

Royal Bank of Canada's MTCR Position: Q1 2023 in Review

Royal Bank of Canada sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 5 shares.

Royal Bank of Canada first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $298K in Q1 2021. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Royal Bank of Canada reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 5 Metacrine, Inc. Common Stock shares in Q1 2023.
  • Royal Bank of Canada first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Royal Bank of Canada's Metacrine, Inc. Common Stock position peaked at $298K in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.